Loading
PP
Progenics Pharmaceuticals Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Velan Capital, L.P., was filed 11 Sept 2019.
Progenics Pharmaceuticals Inc: what insiders have been doing
Progenics Pharmaceuticals Inc is a listed company. Filings by its managers are published through SEC (Form 4). No insider at Progenics Pharmaceuticals Inc has published a filing in the past twelve months. The most recent one dates from 23 June 2020.
Since 2016, the database holds 8 purchases and 11 sales by insiders of the company.
This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
28
Thresholds
n/a
Buy Volume
€4M
8 ops. · all time
Sell Volume
€9M
11 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2019FY ended December 2019 · cache
Income statement
Revenue31.2M
Net income-61.1M-195.9% margin
Last declaration on 23 June 2020
Declarations28 total
50,000 sharesCommon StockSEC:0001437749-20-013676:0
21,202 sharesCommon StockSEC:0001437749-20-013680:0
12,000 sharesCommon StockSEC:0001437749-20-013675:0
4,121 sharesCommon StockSEC:0001437749-20-013678:0
72,023 shares@ US$4.994710.1% of flowCommon Stock, $0.0013 par valueSEC:0000921895-19-002393:0
Canonical exit: 8 Dec 2019 (T+90)
43,520 shares@ US$4.620865.5% of flowCommon Stock, $0.0013 par valueSEC:0000921895-19-002384:0
Canonical exit: 4 Dec 2019 (T+90)
21,480 shares@ US$4.939334.5% of flowCommon Stock, $0.0013 par valueSEC:0000921895-19-002384:1
Canonical exit: 8 Dec 2019 (T+90)
277,424 shares@ US$4.393734.5% of flowCommon Stock, $0.0013 par valueSEC:0000921895-19-002367:0
Canonical exit: 2 Dec 2019 (T+90)
243,614 shares@ US$4.509330.9% of flowCommon Stock, $0.0013 par valueSEC:0000921895-19-002367:1
Canonical exit: 3 Dec 2019 (T+90)
130,826 shares@ US$4.308715.8% of flowCommon Stock, $0.0013 par valueSEC:0000921895-19-002346:0
Canonical exit: 21 Nov 2019 (T+90)
73,230 shares@ US$4.30038.8% of flowCommon Stock, $0.0013 par valueSEC:0000921895-19-002346:1
Canonical exit: 24 Nov 2019 (T+90)
12,000 shares@ US$4.89100.0% of flowCommon StockSEC:0001562180-19-003873:0
10,000 shares@ US$5.33100.0% of flowCommon StockSEC:0001562180-19-003828:0
40,000 shares@ US$5.3580.1% of flowCommon StockSEC:0001562180-19-003659:1
10,000 shares@ US$5.3319.9% of flowCommon StockSEC:0001562180-19-003659:0
52,600 shares@ US$9.702.8% of flowCommon StockSEC:0000919574-17-002069:1
50,000 shares@ US$9.702.7% of flowCommon StockSEC:0000919574-17-002069:2
100,000 shares@ US$9.705.3% of flowCommon StockSEC:0000919574-17-002069:3
150,000 shares@ US$9.557.9% of flowCommon StockSEC:0000919574-17-002069:5
100,000 shares@ US$9.705.3% of flowCommon StockSEC:0000919574-17-002069:0
150,000 shares@ US$9.688.0% of flowCommon StockSEC:0000919574-17-002069:4
100,000 shares@ US$9.745.3% of flowCommon StockSEC:0000919574-17-001117:0
50,000 shares@ US$9.652.6% of flowCommon StockSEC:0000919574-17-001117:1
100,000 shares@ US$9.755.3% of flowCommon StockSEC:0000919574-17-001117:2
100,000 shares@ US$9.665.3% of flowCommon StockSEC:0000919574-17-001117:3
25 of 28 declarations
About Progenics Pharmaceuticals Inc
Progenics Pharmaceuticals Inc is a company focused on developing innovative treatments for cancer-related diseases. It specializes in the research and commercialization of targeted therapies and radiopharmaceuticals.
